Insight Pharma Reports Announces Liquid Biopsy
An Emerging Market for Radically Improved Cancer Management
(firmenpresse) - NEEDHAM, MA -- (Marketwired) -- 06/03/15 -- Insight Pharma Reports, a division of Cambridge Healthtech Institute, announces their Liquid Biopsy Report, focusing on this new emerging market for radically improving cancer management.
The report explores the background, history and basic research of liquid biopsy covering the three sample categories that dominate liquid biopsy today: circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs, also known as exosomes). Also included are the commercial aspects, market dynamics, and trends of liquid biopsy.
Report Highlights Include:
Market dynamics including market size estimates along with five-year projections by application segment, the competitive environment and deal activity
Commercial aspects of liquid biopsy with profiles of over 30 companies
Survey results from117 industry experts conducted by Insight Pharma Reports exclusively for this report.
Exclusive transcripts from extended interviews with:
Nicholas Dracopoli, Ph.D., Vice President Oncology Translational Research, Janssen Pharmaceuticals
Paul Dempsey, Ph.D., Chief Scientific Officer, Cynvenio Biosystems
Johan Skog, Ph.D., CSO and Founding Scientist, Exosome Diagnostics
Lidia Sambucetti, PhD, Sr. Director of Cancer Biology, and Ted Ira, Director of Sales, SRI Biosciences Div.
Harry Glorikian, Life Sciences Consultant
For more information visit:
Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets. Insight Pharma Reports are used by leading pharmaceutical, biotech, diagnostic, consulting, and financial companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. Insight Pharma Reports is a division within Cambridge Healthtech Institute.
For more information:
Kerri Kelley
Insight Pharma Reports
781-972-1347
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 03.06.2015 - 17:30 Uhr
Sprache: Deutsch
News-ID 398039
Anzahl Zeichen: 0
contact information:
Town:
NEEDHAM, MA
Kategorie:
Healthcare
Diese Pressemitteilung wurde bisher 169 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Insight Pharma Reports Announces Liquid Biopsy"
steht unter der journalistisch-redaktionellen Verantwortung von
Insight Pharma Reports (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
